150 related articles for article (PubMed ID: 10681350)
1. Indinavir pharmacokinetics and parmacodynamics in children with human immunodeficiency virus infection.
Gatti G; Vigano' A; Sala N; Vella S; Bassetti M; Bassetti D; Principi N
Antimicrob Agents Chemother; 2000 Mar; 44(3):752-5. PubMed ID: 10681350
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of indinavir/ritonavir 400/100 mg twice daily plus two nucleoside analogues in treatment-naive HIV-1-infected patients with CD4+ T-cell counts <200 cells/mm3: 96-week outcomes.
Mootsikapun P; Chetchotisakd P; Anunnatsiri S; Boonyaprawit P
Antivir Ther; 2005; 10(8):911-6. PubMed ID: 16430196
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of zidovudine compared to stavudine, both in combination with lamivudine and indinavir, in human immunodeficiency virus-infected nucleoside-experienced patients with no prior exposure to lamivudine, stavudine, or protease inhibitors (novavir trial).
Joly V; Flandre P; Meiffredy V; Brun-Vezinet F; Gastaut JA; Goujard C; Remy G; Descamps D; Ruffault A; Certain A; Aboulker JP; Yeni P;
Antimicrob Agents Chemother; 2002 Jun; 46(6):1906-13. PubMed ID: 12019107
[TBL] [Abstract][Full Text] [Related]
4. A phase I/II study of the protease inhibitor indinavir in children with HIV infection.
Mueller BU; Sleasman J; Nelson RP; Smith S; Deutsch PJ; Ju W; Steinberg SM; Balis FM; Jarosinski PF; Brouwers P; Mistry G; Winchell G; Zwerski S; Sei S; Wood LV; Zeichner S; Pizzo PA
Pediatrics; 1998 Jul; 102(1 Pt 1):101-9. PubMed ID: 9651421
[TBL] [Abstract][Full Text] [Related]
5. Lamivudine 300 mg QD versus continued lamivudine 150 mg BID with stavudine and a protease inhibitor in suppressed patients.
Sension MG; Bellos NC; Johnson J; Sepulveda GE; DeJesus E; Santana JL; Ames MH; Goodwin SD
HIV Clin Trials; 2002; 3(5):361-70. PubMed ID: 12407485
[TBL] [Abstract][Full Text] [Related]
6. A pilot trial of indinavir, ritonavir, didanosine, and lamivudine in a once-daily four-drug regimen for HIV infection.
Mole L; Schmidgall D; Holodniy M
J Acquir Immune Defic Syndr; 2001 Jul; 27(3):260-5. PubMed ID: 11464145
[TBL] [Abstract][Full Text] [Related]
7. A comparison of stavudine, didanosine and indinavir with zidovudine, lamivudine and indinavir for the initial treatment of HIV-1 infected individuals: selection of thymidine analog regimen therapy (START II).
Eron JJ; Murphy RL; Peterson D; Pottage J; Parenti DM; Jemsek J; Swindells S; Sepulveda G; Bellos N; Rashbaum BC; Esinhart J; Schoellkopf N; Grosso R; Stevens M
AIDS; 2000 Jul; 14(11):1601-10. PubMed ID: 10983647
[TBL] [Abstract][Full Text] [Related]
8. Clinical and virologic response to combination treatment with indinavir, zidovudine, and lamivudine in children with human immunodeficiency virus-1 infection: a multicenter study in the Netherlands. On behalf of the Dutch Study Group for Children with HIV-1 infections.
van Rossum AM; Niesters HG; Geelen SP; Scherpbier HJ; Hartwig NG; Weemaes CM; Veerman AJ; Suur MH; de Graeff-Meeder ER; Slieker WA; Hop WC; Osterhaus AD; Burger DM; De Groot R
J Pediatr; 2000 Jun; 136(6):780-8. PubMed ID: 10839877
[TBL] [Abstract][Full Text] [Related]
9. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team.
Hammer SM; Squires KE; Hughes MD; Grimes JM; Demeter LM; Currier JS; Eron JJ; Feinberg JE; Balfour HH; Deyton LR; Chodakewitz JA; Fischl MA
N Engl J Med; 1997 Sep; 337(11):725-33. PubMed ID: 9287227
[TBL] [Abstract][Full Text] [Related]
10. A comparison of stavudine plus lamivudine versus zidovudine plus lamivudine in combination with indinavir in antiretroviral naive individuals with HIV infection: selection of thymidine analog regimen therapy (START I).
Squires KE; Gulick R; Tebas P; Santana J; Mulanovich V; Clark R; Yangco B; Marlowe SI; Wright D; Cohen C; Cooley T; Mauney J; Uffelman K; Schoellkopf N; Grosso R; Stevens M
AIDS; 2000 Jul; 14(11):1591-600. PubMed ID: 10983646
[TBL] [Abstract][Full Text] [Related]
11. A pilot study of nevirapine, indinavir, and lamivudine among patients with advanced human immunodeficiency virus disease who have had failure of combination nucleoside therapy.
Harris M; Durakovic C; Rae S; Raboud J; Fransen S; Shillington A; Conway B; Montaner JS
J Infect Dis; 1998 Jun; 177(6):1514-20. PubMed ID: 9607828
[TBL] [Abstract][Full Text] [Related]
12. Abacavir-lamivudine-zidovudine vs indinavir-lamivudine-zidovudine in antiretroviral-naive HIV-infected adults: A randomized equivalence trial.
Staszewski S; Keiser P; Montaner J; Raffi F; Gathe J; Brotas V; Hicks C; Hammer SM; Cooper D; Johnson M; Tortell S; Cutrell A; Thorborn D; Isaacs R; Hetherington S; Steel H; Spreen W;
JAMA; 2001 Mar; 285(9):1155-63. PubMed ID: 11231744
[TBL] [Abstract][Full Text] [Related]
13. Pharmacologic characteristics of indinavir, didanosine, and stavudine in human immunodeficiency virus-infected children receiving combination therapy.
Fletcher CV; Brundage RC; Remmel RP; Page LM; Weller D; Calles NR; Simon C; Kline MW
Antimicrob Agents Chemother; 2000 Apr; 44(4):1029-34. PubMed ID: 10722507
[TBL] [Abstract][Full Text] [Related]
14. Stavudine, lamivudine and indinavir in children with advanced HIV-1 infection: preliminary experience.
Monpoux F; Sirvent N; Cottalorda J; Mariani R; Lefbvre JC
AIDS; 1997 Oct; 11(12):1523-5. PubMed ID: 9342078
[No Abstract] [Full Text] [Related]
15. Effect of zidovudine resistance mutations on virologic response to treatment with zidovudine or stavudine, each in combination with lamivudine and indinavir.
Descamps D; Flandre P; Joly V; Meiffrédy V; Peytavin G; Izopet J; Tamalet C; Zeng AF; Harel M; Lastère S; Aboulker JP; Yéni P; Brun-Vézinet F;
J Acquir Immune Defic Syndr; 2002 Dec; 31(5):464-71. PubMed ID: 12473833
[TBL] [Abstract][Full Text] [Related]
16. Antiviral effect and pharmacokinetic interaction between nevirapine and indinavir in persons infected with human immunodeficiency virus type 1.
Murphy RL; Sommadossi JP; Lamson M; Hall DB; Myers M; Dusek A
J Infect Dis; 1999 May; 179(5):1116-23. PubMed ID: 10191212
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of the protease inhibitor indinavir in human immunodeficiency virus type 1-infected children.
Burger DM; van Rossum AM; Hugen PW; Suur MH; Hartwig NG; Geelen SP; Scherpbier HJ; Hoetelmans RM; Vulto AG; de Groot R;
Antimicrob Agents Chemother; 2001 Mar; 45(3):701-5. PubMed ID: 11181346
[TBL] [Abstract][Full Text] [Related]
18. Open-label study of a twice-daily indinavir 800-mg/ritonavir 100-mg regimen in protease inhibitor-naive HIV-infected adults.
Young B; Fischl MA; Wilson HM; Finn TS; Jensen EH; DiNubile MJ; Zeldin RK
J Acquir Immune Defic Syndr; 2002 Dec; 31(5):478-82. PubMed ID: 12473835
[TBL] [Abstract][Full Text] [Related]
19. An open randomized controlled trial of zidovudine plus lamivudine versus stavudine plus lamivudine.
Foudraine NA; de Jong JJ; Jan Weverling G; van Benthem BH; Maas J; Keet IP; Jurriaans S; Roos MT; Vandermeulen K; de Wolf F; Lange JM
AIDS; 1998 Aug; 12(12):1513-9. PubMed ID: 9727573
[TBL] [Abstract][Full Text] [Related]
20. Switch from ritonavir to indinavir in combination therapy for HIV-1-infected children.
Pelton SI; Stanley K; Yogev R; Fletcher CV; McIntosh K; Wiznia A; Nachman S;
Clin Infect Dis; 2005 Apr; 40(8):1181-7. PubMed ID: 15791520
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
